IP Library Granted Patent US 7,910,138
Granted Patent B2
US 7,910,138 · App. 10/574,422 · Granted Mar 22, 2011

Use of a polyphenol for the treatment of a cancerous or precancerous lesion of the skin

Assignee: MediGene AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,138
App. No.
10/574,422
Granted
Mar 22, 2011
Kind
B2
Abstract

A method for treating cancerous or pre-cancerous lesions of the skin by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto is described herein.

Claims (16)

1. A method for treating a keratosis lesion of the skin of a patient, said method comprising topically administering to the keratosis lesion a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises from about 5% (w/w) to about 20% (w/w) of the mixture of polyphenols, wherein the mixture of polyphenols contains epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, and gallocatechol gallate.

2. The method according to claim 1 , wherein the patient is a human.

3. The method according to claim 1 , wherein the mixture of polyphenols is isolated from a tea or a tea extract.

4. The method according to claim 3 , wherein the tea is a green tea.

5. The method according to claim 1 , wherein the mixture of polyphenols contains (−) -epicatechol, (−)-epicatechol gallate, (−)-epigallocatechol, (−)-epigallocatechol gallate, and (−)-gallocatechol gallate.

6. The method according to claim 1 , wherein the mixture of polyphenols contains about 2-20% (w/w) epicatechol, about 2-20% (w/w) epicatechol gallate, about 1-25% (w/w) epigallocatechol, about 40-75% (w/w) epigallocatechol gallate, and about 0.5-20% (w/w) gallocatechol gallate.

7. The method according to claim 6 , wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−)-epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate and about 4.0% (w/w) of (−)-gallocatechol gallate.

8. The method according to claim 1 , wherein the mixture of polyphenols is combined with an additive.

9. The method according to claim 8 , wherein the additive is selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, propylene glycol monopalmitostearate and isopropyl myristate.

10. The method according to claim 1 , wherein the mixture of polyphenols is contained in a carrier selected from the group consisting of an emulsion, a gel, a cream and an ointment.

11. The method according to claim 1 , wherein the method for treating said lesions is combined with a different anticancer treatment.

12. The method according to claim 11 , wherein the different anticancer treatment is selected from the group consisting of surgery, electrodessication, curettage, excision, Mohs micrographic surgery, radiation, proton therapy, chemotherapy, photodynamic therapy, cryosurgery, laser, immunotherapy, vaccine therapy and biologic therapy.

13. The method according to claim 1 , wherein the keratosis lesion of the skin is selected from the group consisting of actinic keratosis, solar keratosis, hyperkeratosis, and seborrheic keratosis.

14. The method according to claim 13 , wherein the lesion of the skin is actinic keratosis.

15. The method according to claim 1 , wherein the composition comprises about 15% (w/w) mixture of polyphenols.

16. A method for treating an actinic keratosis of the skin of a human, said method comprising topically administering to the actinic keratosis lesion a pharmaceutically effective amount of a polyphenol composition comprising (i) a mixture of polyphenols and (ii) a carrier, wherein the composition comprises about 15% (w/w) mixture of polyphenols, wherein the mixture of polyphenols contains about 10.8% (w/w) of (−)-epicatechol, about 6.5% (w/w) of (−)-epicatechol gallate, about 9.2% (w/w) of (−) -epigallocatechol, about 54.8% (w/w) of (−)-epigallocatechol gallate and about 4.0% (w/w) of (−)-gallocatechol gallate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: MEDIGENE AG
To: FOUGERA PHARMACEUTICALS INC
Reel/Frame 044603/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2006
From: STOCKFLETH, EGGERT
To: MEDIGENE AG
Reel/Frame 017775/0306 →
Continuity (2)
Provisional Application 60510101 · Oct 9, 2003
Related Publication 20070059387A1 · Mar 15, 2007